Two-Year Outcomes of the Randomized Second-Generation Drug-Eluting Stents in Diabetes (SUGAR) Trial

Within the last 24 months, I have financial relationship(s) or affiliation(s) with a manufacturer, marketer, reseller, or distributor of a healthcare product or service involved in the management of patients with any cardiovascular disease to include devices, drugs, and digital health care products listed below:

• Consultant Fee/Honoraria/Speaker's Bureau (Both) - Abbott Vascular; Boston Scientific Corporation; Medtronic; Biomenco